Moderna (MRNA) operating income was -$3.1B in FY2025 (+22% YoY). The tables below show the complete quarterly and annual operating income history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Operating Income
Fiscal Year
Operating Income
YoY
2025
-$3.1B
+22%
2024
-$3.9B
+7%
2023
-$4.2B
-145%
2022
$9.4B
-29%
2021
$13.3B
+1843%
2020
-$763M
-40%
2019
-$546M
-32%
2018
-$413M
-53%
2017
-$269M
-20%
2016
-$224M
Recent Quarterly Operating Income
Quarter
Operating Income
Q2 2026
-$815M
Q1 2026
-$1.4B
Q4 2025
-$857M
Q3 2025
-$260M
Q2 2025
-$907M
Q1 2025
-$1.1B
Q4 2024
-$1.2B
Q3 2024
-$70M
Q2 2024
-$1.4B
Q1 2024
-$1.3B
Q4 2023
$6M
Q3 2023
-$2.0B
Source: MRNA on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.